Andere talen FibroGen, Inc.

Aandelen

FGEN

US31572Q8087

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,9843 ^USD	-8,01%		-24,28%	+11,06%

15/04	Faron Pharmaceuticals herbenoemt voormalig financieel directeur op interim-basis	AN
03/04	Top Middag Decliners	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	24/04
Faron Pharmaceuticals reappoints former finance chief on interim basis	15/04
Top Midday Decliners	03/04
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise	03/04
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02/04
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	02/04
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	26/03
FibroGen : Corporate Presentation – March 2024	19/03
Sector Update: Health Care Stocks Rise Late Afternoon	12/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	12/03
FibroGen Shares Jump After CEO Stock Purchase	12/03
FibroGen Names Deyaa Adib Chief Medical Officer	11/03
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	11/03
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer	11/03
FibroGen : Corporate Presentation – March 2024	06/03
FibroGen: Q4 Earnings Snapshot	26/02
FibroGen regains rights to anemia drug from AstraZeneca	26/02
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Earnings Flash (FGEN) FIBROGEN Reports Q4 Revenue $27.1M, vs. Street Est of $38.8M	26/02
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen FibroGen, Inc.

Aandelen

FGEN

US31572Q8087

Andere talen

Filters